NICE appoints two non-executive members to board
This article was originally published in Scrip
The UK's National Institute for health and Clinical Excellence (NICE) has appointed two new non-executive members to its board for a four-year term:David Hunterjoins as a public health member; he is deputy director of the UK Clinical Research Collaboration centre for translational research in public health, as well as a member of the department of health's health reforms evaluation panel and leadership governance board. Linda Seymour will serve as a lay member. She is head of policy at the Sainsbury Centre for Mental Health; her previous roles include serving as a member of the national research team, evaluating the Health Education Authority's Health at Work in the NHS programme.
You may also be interested in...
The Indian pharmaceutical sector is recognised for its entrepreneurial spirit. Many companies have crafted successful business strategies by offering API manufacturing, drug discovery, CRAMS and other services to global pharmaceutical customers. Others market their products overseas while leveraging growth opportunities on their home turf. The following five domestic companies are well worth watching in 2011.
The Swedish biotech firm Active Biotech has appointed Dr Helén Tuvesson as its new chief scientific officer, effective 1 April. Dr Tuvesson has been with the company since 1998, working in preclinical development, R&D management and most recently within the senior management team. She will report to president and CEO Tomas Leanderson.
Affimed Therapeutics (Germany) has appointed Dr Adi Hoess as its new chief commercial officer. Effective immediately, Mr Hoess will focus on commercial and strategic management and business development, complimenting his previous senior management and business development roles at Jenowis, Carl Zeiss Jena, MorphoSys and Jerini. His appointment also coincides with the continued development of the company's lead product candidate, AFM13, for Hodgkin's lymphoma, which entered a Phase I clinical trial last November (scripintelligence.com, 15 November 2010).